Sermorelin

The honest gap to call out: there is no FDA-approved sermorelin product on the US market today. EMD Serono pulled Geref voluntarily in 2008, and the FDA later confirmed via the Federal Register that the withdrawal was not for safety or effectiveness reasons, purely commercial. That regulatory footnote is now used by US compounding pharmacies as the legal basis to keep producing sermorelin for "wellness" and "anti-ageing" prescribing. So the sermorelin people actually inject in 2026 is almost never the old Geref drug, it is a compounded preparation, usually from a 503A pharmacy on a prescription from a telehealth or men's-health clinic, often stacked with ipamorelin or CJC-1295.

The strongest evidence sits in the original paediatric programme: GHRH(1-29) was shown in the 1980s and 1990s to stimulate GH release in children with idiopathic GH deficiency and to produce modest growth in treated children, which earned Geref its FDA approval in 1990. The 1999 BioDrugs review by Prakash and Goa is the cleanest summary of that paediatric record. Beyond paediatrics the picture thins fast. The 2006 Walker review in Clinical Interventions in Aging makes the case for sermorelin in adult-onset GH insufficiency, but it is a narrative review built on small studies, not a meta-analysis of RCTs, and the author was associated with the manufacturer. No subsequent large randomised trial has tested sermorelin in healthy adults for any of the body-composition, sleep, recovery or longevity claims that drive its current popularity. Almost everything claimed for "wellness" sermorelin in 2026 is extrapolated from (a) the paediatric data, (b) general GH biology, or (c) self-report.

For information only, sermorelin is a prescription medicine and any use should sit under a qualified clinician. The historical Geref label gave 0.03 mg/kg subcutaneously once daily at bedtime in paediatric idiopathic GH deficiency. Modern compounded "wellness" protocols typically describe 100–500 µg subcutaneously once daily at bedtime in adults, sometimes cycled, often combined with ipamorelin or CJC-1295. These adult regimens are not supported by adequately powered clinical trials and the purity and potency of compounded vials are not subject to the same controls as an FDA-approved finished drug. Self-dosing from research-chemical suppliers is unsafe, products are unverified, mislabelling and contamination are documented across the grey market, and pituitary-axis drugs should not be used without monitoring.

In the paediatric record, sermorelin was generally well tolerated. The commonest issues were local injection-site reactions (redness, swelling, pain), occasional flushing and headache, and rare cases of dysphagia or transient hyperactivity. Antibodies against sermorelin were detected in a minority of children on long-term therapy; clinical significance was unclear. Because sermorelin works through the body's own GH/IGF-1 axis, it shares the theoretical long-term concerns of any GH-raising therapy: potential effects on glucose tolerance, the theoretical concern that chronically elevated IGF-1 could accelerate growth of pre-existing cancers, and unknowns around long-term exposure in healthy adults who weren't the original target population. Pregnancy and breastfeeding: avoid. Compounded sermorelin from a 503A pharmacy is not FDA-reviewed for purity, potency or stability the way an approved drug is, and US compounding has had repeated quality incidents across drug categories. People with active malignancy, uncontrolled diabetes, severe respiratory or cardiac illness, or pituitary disease should not use it outside specialist care.